Trials / Completed
CompletedNCT02813252
Long-Term Follow-up Study for Patients Previously Treated With JCAR015
Long-Term Follow-up Protocol for Subjects Treated With JCAR015
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 15 (actual)
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | JCAR015 | No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy. |
Timeline
- Start date
- 2016-08-30
- Primary completion
- 2021-10-22
- Completion
- 2021-10-22
- First posted
- 2016-06-24
- Last updated
- 2022-06-03
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02813252. Inclusion in this directory is not an endorsement.